Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

Treatment of neurodegenerative diseases

Alzheimer’s disease (AD)ihibitionMalattia di Alzheimermultitarget drugsneurodegenerative disorder

Introduction

In the context of multitarget drugs (MTD), the invention refers to the synthesis of new compounds having a broad spectrum of neuroprotective and anti-neurodegenerative properties. The strategy is based on the idea of targeting two or more proteins at the same time with a single compound to obtain therapeutic effects superior to those of a selective drug.

Technical features

Alheizmer’s desease is a progressive neurological disorder characterized by deterioration of cognitive function, dementia, memory loss, and altered behavior. Multitarget drugs (MTD) are emerging as promising disease-modifying compounds for the treatment of complex neurological disorders. MTDs are basically small organic molecules offering various advantages over cocktails or multicomponent drugs, as they are able to hit multiple targets belonging to different pathological pathways.

The invention refers to a novel class of compounds derivating from triazinone. As a result of its inhibitory activity against BACE-1 and GSK-3β, the compound is instrumental in treating various neurodegenerative pathologies, including Alzheimer’s disease.

Possible Applications

  • Treatment of neurodegenerative disorders, for example, Alzheimer’s disease.

Advantages

  • Simplified therapeutic regimen;
  • Improved compliance in aged people;
  • Higher efficacy due to the synergistic effect of simultaneous inhibition of multiple targets;
  • Reduced side effects in case of drug cocktail load.